Last updated: January 19, 2026
rket Dynamics and Financial Trajectory for IOFLUPANE I-123
Executive Summary
IOFLUPANE I-123, marketed under the brand name DaTscan, is a radiopharmaceutical agent used in neuroimaging to diagnose Parkinsonian syndromes and differentiate them from essential tremor. This report analyzes the current market landscape, regulatory environment, clinical applications, competitive positioning, and forecasted financial trajectory. Historical data, licensing agreements, technological trends, and policy impacts inform projections, offering a comprehensive view for stakeholders.
Introduction
IOFLUPANE I-123 is a SPECT (Single Photon Emission Computed Tomography) imaging agent targeting dopamine transporter (DAT) binding sites. Approved by the FDA in 2011 and EMA in 2012, it addresses a critical diagnostic gap in neurology. Its revenue potential depends on the evolving prevalence of Parkinson’s Disease (PD), diagnostic imaging adoption rates, regulatory policies, and technological innovations.
Market Landscape Overview
| Parameter |
Data / Insights |
| Global Parkinson’s Disease Cases (2022) |
Approx. 10 million; projected to reach 12 million by 2040 (WHO) [1] |
| Imaging Modalities for PD |
DAT scans (DaTscan), MRI, PET; DaTscan held ~70% share in diagnostic SPECT agents (2022) |
| Key Players |
GE Healthcare, Jubilant Radiopharma, Lantheus Medical Imaging, Piramal Pharma Solutions |
| Regulatory Approvals |
FDA (2011), EMA (2012), other regions (pending) |
| Market Penetration (2022) |
DaTscan estimated at >60% within neurology imaging, primarily in North America and Europe |
| Pricing (U.S.) |
Approx. $3,000 - $4,000 per dose |
Regulatory and Policy Drivers
| Region |
Status |
Impact |
Notes |
| U.S. |
Approved 2011 |
Strong reimbursement pathways, CMS coverage |
Reimbursement codes: HCPCS code A9580 |
| EU |
Approved 2012 |
Coverage varies; reimbursement limited in some regions |
CE marking obtained |
| Asia-Pacific |
Limited approvals |
Growing market potential |
Strategies include registering in China, Japan |
| Regulatory Trends |
Emphasis on radiopharmaceutical safety and efficacy |
Demand for harmonized standards |
Clinical and Technological Trends
| Trend |
Impact |
Details |
| Advancement in Imaging Technology |
Increased accuracy |
Transition from planar imaging to high-resolution SPECT systems |
| Expansion in Diagnostic Indications |
Beyond PD |
Potential in Lewy body dementia and other movement disorders |
| Personalized Medicine |
Enhanced patient stratification |
Use of DaTscan to guide therapy decisions |
| Alternative Agents |
Competition |
Fludopa-F18 PET imaging agents are emerging but less widespread |
Competitive Positioning
| Company |
Product |
Market Share |
Strengths |
Challenges |
| Jubilant Radiopharma |
DaTscan |
~60% (2022) |
FDA-approved, established distribution |
Pricing pressures |
| GE Healthcare |
Axumin (PET tracer, competition indirectly) |
Variable |
Broad medical imaging portfolio |
Specific to PET, not SPECT |
| Others |
Emerging agents & generic radiotracers |
Niche |
Cost advantages |
Regulatory barriers, limited data |
Financial Trajectory Analysis
Current Revenue Snapshot (2022)
Estimated global sales of IOFLUPANE I-123 (DaTscan) exceeded $250 million, driven predominantly by North America and Europe.
| Revenue Driver |
2022 Figures |
Notes |
| Unit sales |
Approximately 60,000 doses |
Average price: ~$4,000/dose |
| Key Markets |
North America (~70%), Europe (~20%) |
Variability in reimbursement and approval status |
Forecasted Growth Factors
| Factor |
Impact |
Quantitative Estimate |
| Increasing PD prevalence |
Expansion of diagnostic indications |
Compound annual growth rate (CAGR) estimate of 6-8% (2023–2028) |
| Market penetration expansion |
Adoption in remainin regions |
+15% growth potentially achievable through strategic launches |
| Technological advances |
Higher sensitivity leading to broader use |
Moderate uplift in adoption, 2-3% annual growth |
| Reimbursement policies |
Enhancing access |
Potential for 10% revenue boost with improved policies |
Five-Year Revenue Projection (2023–2028)
| Year |
Estimated Global Revenue |
Notes |
| 2023 |
$275 million |
Recovery from pandemic effects, steady adoption |
| 2024 |
$300 million |
Increasing reimbursement, broader regional approvals |
| 2025 |
$330 million |
Expanded clinical use in early-stage PD |
| 2026 |
$360 million |
Entry into emerging markets |
| 2027 |
$385 million |
Technological improvements, higher imaging resolution |
| 2028 |
$410 million |
Maturation of pipeline, sustained growth |
(Note: These forecasts assume stable policies and no significant regulatory setbacks.)
Comparative Analysis: IOFLUPANE I-123 vs Alternatives
| Criterion |
IOFLUPANE I-123 (DaTscan) |
F-Fluorodopa PET |
Clinical Application |
Cost & Reimbursement |
| Approval Status |
FDA, EMA-approved |
Approved in select regions |
PD diagnosis, differential diagnosis |
High costs, variable |
| Imaging Modality |
SPECT |
PET |
Similar purposes but different accuracy profiles |
PET generally costlier |
| Availability |
Widely available in developed markets |
Limited, in research or specialty centers |
Potential for broader access with cost reduction |
Less accessible in emerging markets |
| Market Share |
~60% of neuroimaging agents |
Niche, growing |
Dominates PD diagnosis imaging |
Competitive but less utilized |
Key Challenges and Risks
| Challenge |
Impact |
Mitigation Strategies |
| Regulatory delays |
Market expansion slowdowns |
Engage early with authorities, adaptive strategies |
| Pricing pressures |
Revenue compression |
Value-based reimbursement negotiations |
| Market saturation |
Limited growth in mature markets |
Geographic expansion, new indications |
| Emerging competitors |
Market share erosion |
Continuous innovation, strategic alliances |
Opportunities and Strategic Considerations
| Opportunity |
Actionable Move |
Expected Outcome |
| Expansion into Asia-Pacific |
Collaborate with regional partners |
Grow market share in high-growth regions |
| Development of Next-Generation Agents |
Invest in R&D |
Maintain competitive edge and access new indications |
| Reimbursement Advocacy |
Engage payer bodies |
Enhance coverage and patient access |
| Technological Innovations |
Upgrade imaging infrastructure |
Increase diagnostic accuracy and utilization |
Summary of Market Dynamics & Financial Trajectory
- Prevalence and Diagnostic Need: Rising PD cases bolster demand for IOFLUPANE I-123.
- Regulatory Approvals and Coverage: Crucial in market expansion; established approval supports sustained revenue growth.
- Competitive Landscape: Dominated by Jubilant Radiopharma; innovation and strategic regional entry are key.
- Financial Forecast: Continued CAGR of 6-8% projected, reaching approximately $410 million globally by 2028.
- Market Drivers & Barriers: Adoption driven by technological advancement and reimbursement policies; barriers include high costs and regulatory hurdles.
Key Takeaways
- IOFLUPANE I-123 remains a pivotal diagnostic agent in neuroimaging for Parkinsonian syndromes, with a stable and expanding market.
- Growth prospects are favorable, driven by increasing PD prevalence, technological advancements, and regional approvals.
- Regulatory and reimbursement landscapes significantly influence revenue trajectories; proactive engagement enhances market penetration.
- Competitive differentiation hinges on technological innovation, regional expansion, and cost optimization.
- Strategic adaptation to emerging imaging agents and expanding indications will be critical for sustained financial performance.
FAQs
Q1: What factors most influence IOFLUPANE I-123’s revenue growth?
A: Prevalence of Parkinson’s Disease, regulatory approvals, reimbursement policies, technological adoption, and regional market expansion.
Q2: How does IOFLUPANE I-123 compare to PET-based imaging agents?
A: While PET agents offer higher resolution, IOFLUPANE I-123 via SPECT remains more accessible, cost-effective, and has broader regulatory approval, especially in developed markets.
Q3: What are the major regulatory hurdles facing IOFLUPANE I-123?
A: Variability in approval processes across regions, delays in application approvals, and reimbursement policy differences.
Q4: Which regions present the highest growth opportunities for IOFLUPANE I-123?
A: Asia-Pacific countries like China and Japan, along with expanding markets in Latin America and the Middle East.
Q5: How will technological innovations impact the market?
A: Improvements in SPECT imaging technology will enhance diagnostic accuracy, boost adoption, and potentially justify higher pricing.
References
- World Health Organization (WHO). “Global Parkinson’s Disease Data,” 2022.
- Jubilant Radiopharma. “DaTscan Product Information,” 2022.
- U.S. Food and Drug Administration (FDA). “DaTscan (IOFLUPANE I-123) Approval Documentation,” 2011.
- European Medicines Agency (EMA). “DaTscan Market Authorization,” 2012.
- MarketsandMarkets. “Neurodegenerative Disease Market,” 2022.
